



PTO/SB/OBA (04-07)

Approved for use through 09/30/2007. OMB 0654-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 12

Complete if Known

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1

of 3

Application Number	10/633,630
Filing Date	August 5, 2003
First Named Inventor	Klaus GIESE, et al.
Art Unit	1635
Examiner Name	Kimberly Chong
Attorney Docket Number	14677-003US

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup> (if known)			
	A1	6,239,272	05/29/2001	BEIGELMAN et al.	
	A2	6,107,094	08/22/2000	CROOKE	
	A3				
	A4				

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	B1	WO 03/070895	08/28/2003	RIBOZYME PHARM. INC.		
	B2	WO 99/55857	11/04/1999	RIBOZYME PHARM. INC.		
	B3	WO 02/097114	12/05/2002	RIBOZYME PHARM. INC.		
	B4	WO 97/46570	12/11/1997	ISIS PHARM, INC..		
	B5	WO 96/18736	06/20/1996	RIBOZYME PHARM. INC.		
	B6	WO 02/16620	02/28/2002	UNIV. OF SHEFFIELD		
	B7	WO 92/07065	04/30/1992	MAXPLANCK-GESELLSCHAFT		
	B8	WO 02/44321	06/06/2002	MAXPLANCK-GESELLSCHAFT		
	B9	WO 03/070918	08/28/2003	RIBOZYME PHARM. INC.		
	B10	WO 94/01550	01/20/1994	HYBRIDON, INC.		
	B11	EP 1 214 945 B1	06/08/2005	ALYNYLAM EUROPE AG		
	B12					
	B13					

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/633,630
Filing Date	August 5, 2003
First Named Inventor	Klaus GIESE, et al.
Art Unit	1635
Examiner Name	Kimberly Chong
Attorney Docket Number	14677-003US

Sheet

2

of

3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		P. DAN COOK, "Medicinal Chemistry of Antisense Oligonucleotides"; (ed. Croke, S.T.), pp 29-56 Marcel Dekker, NY 2001	
		PARRISH et al., "Functional Anatomy of a dsRNA Trigger;" (2000) Molecular Cell 6, 1077-1087	
		BEVILACQUA and Cech; "Minor-Groove Recognition of Double-Stranded RNA by the Double-Stranded RNA-Binding;" Biochemistry 1996, 35, 9983-9994	
		WU, et al., "Identification and Partial Purification of Human Double Strand RNase Activity"; The Journal of Biological Chem; Vol. 273, No. 6, 2532-2542 (1998)	
		US 60/386,782 (priority document for D1 (Opp.II), pre-dating the earliest priority date of the opposed patent)	
		M. MONOHARAN; "2'-Carbohydrate modifications in antisense oligonucleotide therapy...;" Biochimica et Biophysica Acta; (1999) 117-130	
		INOUE et al., "Synthesis and hybridization studies on two complementary nona (2'-O-methyl)ribonucleotides"; Nucleic Acids Res. 1987, 15:6131-48	
		US 10/205,309; (priority document for No. 1, filed on July 25, 2002)	
		FIRE, "RNA-triggered gene Silencing;" TIG, Vol. 15, No. 9, 358-363	
		PADDISON, et al., "Stable suppression of gene expression by RNAi in mammalian cells;" PNAS, 99(3); 99 1443-1448; (2002)	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/633,630
Filing Date	August 5, 2003
First Named Inventor	Klaus GIESE, et al.,
Art Unit	1635
Examiner Name	Kimberly Chong
Attorney Docket Number	14677-003US

Sheet 3

of

3

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
		PARK, et al., "Prevention of HIV-1 infection in human peripheral blood mononuclear cells by specific RNA interference," Nucleic Acids Res., vol. 30, No. 22, pp 4830-4835; (2002)	
		HARBORTH, et al., "Identification of essential genes in cultured mammalian cells using small interfering RNAs," J Cell Science; 114: pp 4557-4565; (2001)	
		KURRECK, "Improvement through novel chemical modifications;" Eur. J. Biochem, 270, 1628-1644 (2003)	
		ROSE, et al., "Functional polarity is introduced by Dicer processing of short substrate RNAs;" Nucleic Acids Research, 2005, Vol. 33, No. 13, pp.4140-4156	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.